BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yee NS. Update in Systemic and Targeted Therapies in Gastrointestinal Oncology. Biomedicines 2018;6:E34. [PMID: 29547556 DOI: 10.3390/biomedicines6010034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Orlandi P, Gentile D, Banchi M, Cucchiara F, Di Desidero T, Cremolini C, Moretto R, Falcone A, Bocci G. Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. Invest New Drugs 2020;38:92-8. [DOI: 10.1007/s10637-019-00804-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Han D, Yu T, Dong N, Wang B, Sun F, Jiang D. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res 2019;38:289. [PMID: 31277685 DOI: 10.1186/s13046-019-1289-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
3 McGillen KL, Zaidi S, Ahmed A, Harter S, Yee NS. Contrast-Enhanced Ultrasonography for Screening and Diagnosis of Hepatocellular Carcinoma: A Case Series and Review of the Literature. Medicines (Basel) 2020;7:E51. [PMID: 32867068 DOI: 10.3390/medicines7090051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Roviello G, Petrioli R, Rosellini P, Multari AG, Conca R, Paganini G, Chiriacò G, Aieta M. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. Invest New Drugs 2019;37:524-30. [DOI: 10.1007/s10637-019-00725-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Wu L, Wang W, Tian J, Qi C, Cai Z, Yan W, Xuan S, Shang A. Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer. Bioengineered 2022;13:1942-51. [PMID: 35019820 DOI: 10.1080/21655979.2021.2023997] [Reference Citation Analysis]
6 Xiang Z, Chen W, Zhang J, Song S, Xia GK, Huang XY, Xie J, Yu Y, Zhang QY. Identification of discrepancy between CTLA4 expression and CTLA4 activation in gastric cancer. Immunopharmacol Immunotoxicol 2019;41:386-93. [PMID: 30422018 DOI: 10.1080/08923973.2018.1533968] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Chen WX, Li GX, Hu ZN, Zhu P, Zhang BX, Ding ZY. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review. Medicine (Baltimore) 2019;98:e17832. [PMID: 31702638 DOI: 10.1097/MD.0000000000017832] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
8 Yee NS, Lee NP. Special Issue: Cancer Biomarkers and Targets in Digestive Organs. Biomedicines 2019;7:E3. [PMID: 30609746 DOI: 10.3390/biomedicines7010003] [Reference Citation Analysis]
9 Zhang Y, Wu W, Sun Q, Ye L, Zhou D, Wang W. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition. Mol Med Rep 2021;23:340. [PMID: 33760121 DOI: 10.3892/mmr.2021.11979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sur D, Havasi A, Cainap C, Samasca G, Burz C, Balacescu O, Lupan I, Deleanu D, AlexandruIrimie. Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. J Clin Med 2020;9:E182. [PMID: 31936611 DOI: 10.3390/jcm9010182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
11 Zhang X, Zhang X, Han R, Wang Z, Yang Q, Huang Y, Yan Y. BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro. Biochemical and Biophysical Research Communications 2022;595:22-7. [DOI: 10.1016/j.bbrc.2022.01.067] [Reference Citation Analysis]
12 Li A, Wang K, Xu A, Wang G, Miao Y, Sun Z, Zhang J. Apatinib as an optional treatment in metastatic colorectal cancer. Medicine (Baltimore) 2019;98:e16919. [PMID: 31464927 DOI: 10.1097/MD.0000000000016919] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]